| FY 2004 (No.200-211) |
Japanese
version
issued
on |
No. |
Table of contents |
Posted
on |
PDF |
| March 31, 2005 |
211 |
- 1.
- Important Safety Information
- (1)
- Raloxifene Hydrochloride
- (2)
- Quetiapine Fumarate
- (3)
- Blood Glucose Self-monitoring Kit(those using the glucose dehydrogenase method and coenzyme pyroloquinoline quinone)
- 2.
- Revision of PRECAUTIONS (No. 164)
Trandolapril(and 4 others)
|
|
(Full text) |
| February 24, 2005 |
210 |
- 1.
- Leflunomide-related interstitial pneumonia
- 2.
- Important Safety Information
- (1)
- Epirubicin Hydrochloride
- (2)
- Freeze-dried Sulfonated Human Normal Immunoglobulin, pH4 Treated Acidic Human Normal Immunoglobulin, Polyethylene Glycol Treated Human Normal Immunoglobulin, Freeze-dried Polyethylene Glycol Treated Human Normal Immunoglobulin
- (3)
- Telithromycin
- (4)
- Prednisolone (oral dosage form)
- (5)
- Mizoribine
- 3.
- Revision of PRECAUTIONS (No. 163)
Mefenamic Acid (and 11 others)
|
|
(Full text) |
| January 27, 2005 |
209 |
- 1.
- Important Safety Information
- (1)
- Phtharal
- 2.
- Revision of PRECAUTIONS (No. 162)
Lisinopril (and 8 others)
|
|
(Full text) |
| December 21, 2004 |
208 |
- 1.
- Important Safety Information
- (1)
- Interferon Alfa (NAMALWA)
- (2)
- Telithromycin
- 2.
- Revision of PRECAUTIONS (No. 161)
Amitriptyline Hydrochloride (and 13 others)
|
|
(Full text) |
| November 25, 2004 |
207 |
- 1.
- Important Safety Information
- (1)
- Paclitaxel
- (2)
- Sodium Rabeprazole
- 2.
- Revision of PRECAUTIONS (No. 160)
Flurbiprofen (oral dosage form) (and 13 others)
|
|
(Full text) |
| October 28, 2004 |
206 |
- 1.
- Safety measures for shock etc. due to injectable antibiotics etc.
- 2.
- Reports on Iressa Tablets 250 prospective study(special investigation)
- 3.
- Safety measures for blood glucose monitoring kits
|
|
(Full text) |
| September 30, 2004 |
205 |
- 1.
- Reports on adverse reactions associated with influenza vaccines in FY2003
- 2.
- Post-marketing safety measures for ticlopidine hydrochloride products and Cypher Stent
- 3.
- Important Safety Information
- (1)
- Tacrolimus Hydrate (oral dosage form, injectable dosage form)
- 4.
- Revision of PRECAUTIONS (No. 159)
Sevoflurane (and 14 others)
|
|
(Full text) |
| August 26, 2004
|
204 |
- 1.
- Important Safety Information
- (1)
- Argatroban
- (2)
- Mosapride Citrate
- (3)
- Salicylamide/Acetaminophen/Anhydrous Caffeine /Promethazine Methylenedisalicylate
- (4)
- Concentrated Glycerin/Fructose
- 2.
- Revision of PRECAUTIONS (No. 158)
Cabergoline (and 12 others)
|
|
(Full text) |
| July 29, 2004
|
203 |
- 1.
- Serious skin disorders caused by pharmaceuticals
- 2.
- Effects of electromagnetic waves from antitheft devices, etc. on medical devices
- 3.
- Important Safety Information
- (1)
- Monoethanolamine Oleate
- (2)
- Clarithromycin
- (3)
- Tegafur/Gimeracil/Oteracil Potassium
- (4)
- Melphalan (injectable dosage form)
- 4.
- Revision of PRECAUTIONS (No. 157)
Milnacipran Hydrochloride (and 6 others)
|
|
(Full text) |
| June 24, 2004
|
202 |
- 1.
- Safety measures relating to pharmaceuticals with high risks resulting from mix-ups
- 2.
- Important Safety Information
- (1)
- Infliximab (Genetical recombination)
- (2)
- Imatinib Mesilate
- (3)
- Oseltamivir Phosphate
- 3.
- Revision of PRECAUTIONS (No. 156)
Tandospirone Citrate (and 5 others)
|
|
(Full text) |
| May 27, 2004
|
201 |
- 1.
- Important Safety Information
- (1)
- Clofedanol Hydrochloride
- (2)
- Flavoxate Hydrochloride
- (3)
- Vinorelbine Ditartrate
- (4)
- Phtharal
- (5)
- Fluorouracil (injectable dosage form)
- (6)
- Doxazosin Mesilate
- (7)
- Sodium Risedronate Hydrate
- 2.
- Revision of PRECAUTIONS (No. 155)
Lornoxicam (and 18 others)
|
|
(Full text) |
| April 22, 2004
|
200
|
- 1.
- Prevention of overdose by use of OptiPen Pro-1 (insulin self-injection device)
- 2.
- Crude drugs and drug products with possible adverse reaction when mistakenly imported due to the similarity in names
- 3.
- Change of URL in response to the establishment of the Pharmaceuticals and Medical Devices Agency
- 4.
- Health hazard caused by natural health foods and non-approved drugs
|
|
(Full text) |
